# US 11,307,209 B2 · Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,307,209 B2
- Document ID: US11307209B2
- Status: Granted
- Kind: B2
- Application number: 15/100,226
- Filed: 2014-12-03
- Published: 2017-01-05
- Granted: 2022-04-19
- Earliest claimed: 2013-12-03
- Assignees: Cezanne S.A.S.
- Applicants: CéZanne S.A.S.
- Inventors: Gaïané Demirdjian; Delphine Espinasse
- Web page: https://patentgrep.com/patent/US11307209B2

## CPC

- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- C07K 16/22: against growth factors {; against growth regulators}
- G01N 33/689: {related to pregnancy or the gonads}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.

## Claims

### Claim 1

A method for the diagnosis, prognosis, risk assessment, and/or risk stratification of preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate in a pregnant female subject, comprising an immunoassay method for the detection of placental growth factor 2 (PlGF-2) comprising:
(a) contacting a sample suspected of comprising PlGF-2 with a first antibody or an antigen-binding fragment thereof specific for PlGF and a second antibody or an antigen-binding fragment thereof, specific for PlGF-2 under conditions allowing for the formation of a ternary complex between PlGF-2 and the two antibodies or antigen-binding fragments thereof,
wherein the first antibody is an antibody provided by R&D Systems Europe Ltd. Abingdon UK under Ref. No.: AF-264-PB (polyclonal anti-PlGF antibody),
wherein the second antibody is the antibody which is produced by a hybridoma cell line selected from the group consisting of the cell line 477/G2 deposited as DSM ACC3222 and the cell line 477/ES deposited as DSM ACC3221;
(b) detecting the binding of the two antibodies or antigen-binding fragments thereof to PlGF-2;
(c) determining the level of placental growth factor 2 (PlGF-2) in a sample from the subject; and
(d) comparing the determined level in the sample to a control level of PlGF-2 derived from subjects without preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate;
wherein a decreased level of PlGF-2 in the sample from the subject as compared to the control level is indicative for preeclampsia, increased risk of acquiring preeclampsia, increased risk of aggravation of preeclampsia, increased risk of delivery of a child with an aneuploidy, increased risk of an aggravation of the risk of delivery of a child with an aneuploidy, increased risk of delivery of a small for gestational age neonate, and/or increased risk of an aggravation of the risk of delivery of a small for gestational age neonate.

### Claim 2 (depends on 1)

The method for diagnosing preeclampsia or the risk of delivery of a child with an aneuploidy or the risk of delivery of a small for gestational age neonate in the pregnant female subject of claim 1, wherein the level of placental growth factor 2 (PlGF-2) is determined in a sample from the subject to be diagnosed and wherein a level of PlGF-2 below a “multiple of the median” (MoM) of 0.85 of the control group is indicative for the prenatal disorder or condition.

### Claim 3 (depends on 1)

The method of claim 1, wherein said subject is in the first trimester of pregnancy.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one further parameter relevant for diagnosis of preeclampsia is determined in the sample, optionally wherein
(a) the disorder or condition is preeclampsia and the further parameter preeclampsia is one or more selected from the group consisting of PAPPA, ultrasound markers (Pulsatile-Index, diastolic notching), Mean Arterial Pressure, PlGF, sFlt, maternal history, soluble Endoglin (sEng), inhibin A, activin A, vascular endothelial growth factor (VEGF), human chorionic gonadotrophin (hCG) and cell free fetal DNA,
(b) the disorder or condition is aneuploidy and the further parameter is one or more selected from the group consisting of PAPP-A, free-beta hCG, nuchal translucency, maternal age, AFP, PlGF, fetal nasal bone, biparietal diameter/nasal bone ratio, hCG, inhibin A, unconjugated estriol 3 (uE3), and cell free fetal DNA, or
(c) the disorder or condition is small for gestational age and the further parameter is one or more selected from the group consisting of PAPP-A, maternal history, PlGF, sFlt, AFP, free-beta hCG, hCG, inhibin-A, activin A, sEng, symphysis-fundal height (SFH), fetal biometry (femur length (FL), head circumference (HC), biparietal diameter (BPD), abdominal circumference (AC)) and ultrasound markers (Pulsatile-Index, Umbilical artery Doppler, Middle cerebral artery Doppler, Ductus venosus Doppler).

### Claim 5

A method for the diagnosis, prognosis, risk assessment, and/or risk stratification of preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate in a pregnant female subject, comprising an immunoassay method for the detection of placental growth factor 2 (PlGF-2) comprising:
(a) contacting a sample suspected of comprising PlGF-2 with a first antibody or an antigen-binding fragment thereof specific for PlGF and a second antibody or an antigen-binding fragment thereof, specific for PlGF-2,
wherein the first antibody is an antibody provided by R&D Systems Europe Ltd. Abingdon UK under Ref. No.: AF-264-PB (polyclonal anti-PlGF antibody),
wherein the second antibody is the antibody produced by a hybridoma cell line selected from the group consisting of the cell line 477/G2 deposited as DSM ACC3222 and the cell line 477/ES deposited as DSM ACC3221;
(b) detecting the binding of the two antibodies or antigen-binding fragments thereof to PlGF-2;
(c) determining the level of placental growth factor 2 (PlGF-2) in a sample from the subject; and
(d) comparing the determined level in the sample to a control level of PlGF-2 derived from subjects without preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate;
wherein a decreased level of PlGF-2 in the sample from the subject as compared to the control level is indicative for preeclampsia, increased risk of acquiring preeclampsia, increased risk of aggravation of preeclampsia, increased risk of delivery of a child with an aneuploidy, increased risk of an aggravation of the risk of delivery of a child with an aneuploidy, increased risk of delivery of a small for gestational age neonate, and/or increased risk of an aggravation of the risk of delivery of a small for gestational age neonate.